Skip to main content
SpringerLink
Log in

Laboratory Methods for the Assay of Tissue Factor Pathway Inhibitor in Human Plasma

  • Protocol
  • First Online:
Haemostasis

Part of the book series: Methods in Molecular Biology ((MIMB,volume 992))

Abstract

Tissue factor pathway inhibitor (TFPI) is being assayed with increasing frequency by researchers attempting to further understand the complexities of the coagulation system. There are a number of methods available for measurement of TFPI; however immunological measurement by ELIZA is the most common assay used. There are a number of commercial kits available for this assay and close attention to detail is critical for accurate results.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletech JP (1988) The lipoprotein-associated coagulation inhibitor that inhibits the factorVII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 71:335–343

    PubMed  CAS  Google Scholar 

  2. Sandset PM, Abildgaard U, Pettersen M (1987) A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 47:389–400

    Article  PubMed  CAS  Google Scholar 

  3. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletech JP, Broze GJ Jr (1989) Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338:518–520

    Article  PubMed  CAS  Google Scholar 

  4. Novotny WF, Girard TJ, Miletech JP, Broze GJ Jr (1989) Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264:18832–18837

    PubMed  CAS  Google Scholar 

  5. Dahm AEA, Andersen TO, Rosendaal F, Sandset PM (2005) A novel anticoagulant activity assay of tissue factor pathway inhibitor 1 (TFPI). J Thromb Haemost 3:651–658

    Article  PubMed  CAS  Google Scholar 

  6. Wesselschmidt R, Likert KM, Girard T, Wun TC, Broze GJ Jr (1992) Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 79:2004–2010

    PubMed  CAS  Google Scholar 

  7. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ Jr, Schwartz AL (1995) The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 95:1773–1781

    Article  PubMed  CAS  Google Scholar 

  8. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP (1990) Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci 87:8869–8873

    Article  PubMed  CAS  Google Scholar 

  9. Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar VV, Lupu C (2000) Expression localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 20:1362–1373

    Article  PubMed  CAS  Google Scholar 

  10. Sandset PM, Abildgaard U, Larsen ML (1988) Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50:803–813

    Article  PubMed  CAS  Google Scholar 

  11. Novotny WF, Girard JJ, Miletech JP, Broze GJ (1988) Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 72:2020–2025

    PubMed  CAS  Google Scholar 

  12. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U (1991) Tissue factor pathway inhibitor with high anticoagulant activity is increased in postheparin plasma and in plasma from cancer patients. Thromb Res 2:713–721

    CAS  Google Scholar 

  13. Hansen JB, Huseby KR, Huseby NE, Ezban M, Nordoy A (1997) Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor induced coagulation in vitro. Thromb Res 85:413–425

    Article  PubMed  CAS  Google Scholar 

  14. Sandset PM, Bendz B (1997) Tissue factor pathway inhibitor: clinical deficiency states. Thromb Haemost 78:467–470

    PubMed  CAS  Google Scholar 

  15. Novotny WF, Brown SG, Miletech JP, Rader DJ, Broze GJ Jr (1991) Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 78:387–393

    PubMed  CAS  Google Scholar 

  16. Dahm AEA, van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM (2003) Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101:4387–4392

    Article  PubMed  CAS  Google Scholar 

  17. Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariens RAS (2001) Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 113:537–543

    Article  PubMed  CAS  Google Scholar 

  18. Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Morishita E, Yamazaki M, Suga Y, Takami A, Miyamoto K, Nakao S (2001) Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. Blood Coagul Fibrinolysis 12:1–8

    Article  PubMed  CAS  Google Scholar 

  19. Adams MJ, Cardigan RA, Marchant WA, Grocott MPW, Mythen MG, Mutch M, Purdy G, Mackie IJ, Machin SJ (2002) Tissue factor pathway inhibitor antigen and activity in 96 patients receiving heparin for cardiopulmonary bypass. J Cardiothorac Vasc Anesth 16:59–63

    Article  PubMed  Google Scholar 

  20. Donahue BS, Gailani D, Mast AE (2006) Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass. J Thromb Haemost 4:1011–1016

    Article  PubMed  CAS  Google Scholar 

  21. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hanssen TA, Nordoy A (1995) Effect of cholesterol lowering on intravascular pools of TFPI and its antigoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 15:879–885

    Article  PubMed  CAS  Google Scholar 

  22. Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordoy A (1996) Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 76:703–709

    PubMed  CAS  Google Scholar 

  23. Ariens RAS, Alberio G, Moia M, Mannucci PM (1999) Low levels of Heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost 81:203–207

    PubMed  CAS  Google Scholar 

  24. Harris GM, Stendt CL, Vollenhoven BJ, Gan TE, Tipping PG (1999) Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Haematol 60:175–180

    Article  CAS  Google Scholar 

  25. Warr TA, Warn-Cramer BJ, Rao LV, Rapaport SI (1989) Human plasma extrinsic inhibitor activity: I. Standardization of assay and evaluation of physiologic variables. Blood 74:201–206

    PubMed  CAS  Google Scholar 

  26. Jeske W, Hoppensteadt D, Fareed J, Bermes E (1995) Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations. Blood Coagul Fibrinolysis 6:S73–S80

    Article  PubMed  CAS  Google Scholar 

  27. Adams MJ, Oostryck R (2000) A comparative study of functional assays for tissue factor pathway inhibitor using normal plasma and clinical samples. Blood Coagul Fibrinolysis 11:327–333

    Article  PubMed  CAS  Google Scholar 

  28. Bendz B, Andersen TO, Sandset PM (2000) A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1. Thromb Res 97:463–472

    Article  PubMed  CAS  Google Scholar 

  29. Ma Q, Tobu M, Schultz C, Jeske W, Hoppensteadt D, Walenga J, Cornelli U, Lee J, Linhardt R, Hanin I, Fareed J (2007) Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thromb Res 119:653–661

    Article  PubMed  CAS  Google Scholar 

  30. Kokawa T, Abumiya T, Kimura T, Harada-Shiba M, Koh H, Tsushima M, Yamamoto A, Kato H (1995) Tissue factor pathway inhibitor activity in human plasma. Arterioscler Thromb Vasc Biol 15:504–510

    Article  PubMed  CAS  Google Scholar 

  31. Hubbard AR, Weller LJ, Gray E (1994) Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coagul Fibrinolysis 5:819–823

    Article  PubMed  CAS  Google Scholar 

  32. Chromogenix R&D, IL (2002) Determination of TFPI activity in plasma with S-2222 (microplate method). Res Methods

    Google Scholar 

  33. Berrettini M, Malaspina M, Parise P, Lucarelli G, Kisiel W, Nenci G (1995) A simple chromogenic substrate assay of tissue factor pathway inhibitor activity in plasma and serum. Am J Clin Pathol 103:391–395

    PubMed  CAS  Google Scholar 

  34. American-Diagnostica. ACTICHROME® TFPI Activity Assay, Product Information Assay Insert

    Google Scholar 

  35. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A (1994) Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb Vasc Biol 14:223–229

    Article  CAS  Google Scholar 

  36. Nordfang O, Valentin S, Beck TC, Hedner U (1991) Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 66:464–467

    PubMed  CAS  Google Scholar 

  37. American-Diagnostica. IMUBIND® Total TFPI ELISA Kit Product No. 849, Product Information Assay Insert

    Google Scholar 

  38. American-Diagnostica. IMMUBIND® Truncated TFPI ELISA Product No. 850

    Google Scholar 

  39. Stago-Diagnostica. Asserachrom® Total TFPI ELISA assay, Product Information Assay Insert

    Google Scholar 

  40. Stago-Diagnostica. Asserachrom® Free TFPI ELISA assay, Product Information Assay Insert

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Haematology Research Laboratory, Murdoch Children’s Research Institute, Melbourne, Australia

    Robyn Summerhayes

Authors
  1. Robyn Summerhayes
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Paediatrics, University of Melbourne, n/a, Parkville, 3052, Victoria, Australia

    Paul Monagle

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Humana Press

About this protocol

Cite this protocol

Summerhayes, R. (2013). Laboratory Methods for the Assay of Tissue Factor Pathway Inhibitor in Human Plasma. In: Monagle, P. (eds) Haemostasis. Methods in Molecular Biology, vol 992. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-339-8_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-339-8_22

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-338-1

  • Online ISBN: 978-1-62703-339-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation